Dr. Leonard Schleifer, CEO, Regeneron
Scott Mlyn | CNBC
Regeneron’s monoclonal antibodies grant months of safety from Covid-19 and may very well be administered to people whose immune techniques aren’t shielded sufficient by vaccines, CEO Len Schleifer instructed CNBC’s “Squawk Box” Monday.
Schleifer’s feedback got here after Regeneron launched information that indicated its one-dose antibody cocktail minimize the danger of catching the virus by almost 82% for two to eight months. Regeneron’s monoclonals have been administered intravenously to deal with as much as reasonable Covid signs throughout the pandemic and decrease the possibilities for hospitalization in high-risk sufferers, in response to the Food and Drug Administration.
“If you want to protect people on a population level, vaccines are the best way to go – they’re cheap and you can make billions of doses,” Schleifer stated. “But our data now indicates that antibodies are the key player in the sense that they are sufficient.”
“You might not need the cellular immunity. It might add something, but antibodies are sufficient based on these data to protect you from getting Covid-19,” he added.
